A5028703675- Chemotherapy-related skin toxicity
- Hair Growth and Disorders
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Nonmelanoma Skin Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Wound Healing and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Biomedical Ethics and Regulation
- Autoimmune Bullous Skin Diseases
- Oral health in cancer treatment
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Hematopoietic Stem Cell Transplantation
- Nursing education and management
- Urticaria and Related Conditions
- Psoriasis: Treatment and Pathogenesis
- Medication Adherence and Compliance
- Nursing Roles and Practices
- Retinoids in leukemia and cellular processes
- Electronic Health Records Systems
- Palliative Care and End-of-Life Issues
Mount Sinai Hospital
2020-2024
Tisch Hospital
2023
Cancer Institute (WIA)
2023
Tisch Cancer Institute
2023
Icahn School of Medicine at Mount Sinai
2021-2023
Memorial Sloan Kettering Cancer Center
2013-2019
University of Miami
2017
Roche (Switzerland)
2016
Actelion (Switzerland)
2016
Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, mAbs cause cutaneous immune-related adverse events. Although the most commonly reported toxicities are mild, a subset persist despite therapy can lead to severe or life-threatening toxicity. Autoimmune blistering disorders not associated with mAb therapy. We...
Abstract Background Dermatologic adverse events (dAEs) of anticancer therapies may negatively impact dosing and quality life. While therapy interruption patterns due to dAEs have been studied in hospitalized cancer patients, similar outcomes outpatient oncodermatology are lacking. Objectives To analyse the patterns, clinico‐histopathologic characteristics management dermatology consultations for acute attributed most frequently interrupted class oncologic agents. Methods We performed a...
Management of cancer treatment-related skin toxicities can minimize treatment disruptions and improve patient well-being.This guideline aims to support patients clinicians in decisions regarding management toxicities.A panel developed a for using GRADE (Grading Recommendations, Assessment, Development, Evaluation) certainty evidence the National Academies Sciences, Engineering, Medicine criteria trustworthy guidelines. The Cochrane risk-of-bias tool assessed risk bias. A quantitative or...
This document acts as the clinical summary component of ONS Guidelines™ for management cancer treatment–related skin toxicity (Williams et al., 2020), developed by a panel oncology healthcare professionals after rigorous systematic review high-quality randomized trials. The guideline is designed to establish evidence-based efficacy interventions prevent and manage toxicities. Sources evidence have been divided into pharmacologic nonpharmacologic interventions.
Outpatient oncology nurses are responsible for symptom assessment/management and care coordination during telephone triage. Nursing triage interventions can improve patient outcomes clinical efficiency. Therefore, the lack of education training in greatly impact care.Using a prospective pretest/posttest design, we sought to determine if educational workshop would nurses' knowledge, confidence, skill over 12 weeks.The intervention incorporated an online didactic lecture, group case scenario,...
Background Mycosis fungoides is the most common type of cutaneous T-cell lymphoma (CTCL), yet frequently misdiagnosed and perplexing to those who may not be familiar with disease process management. Therefore, nursing involvement in interdisciplinary referral from a generalist specialist key improving patient outcomes early detection mycosis fungoides. Purpose Study/Inquiry This manuscript elucidates role patients CTCL, importance clinical grasp approach for referrals, factors consider when...
Charge nurses often act as the eyes and ears of unit. They are leaders, clinical experts, educators, policy enforcers, patient advocates. ensure patients caregivers receive high-quality, safe, evidence-based care. With shift in health care from in-patient to outpatient setting, becoming more acute complex for staff nurses. pivotal successful management these patients. Unfortunately, charge minimal training placed this role with inadequate preparation support. This can lead feelings anxiety,...
e12500 Background: Late effects such as persistent alopecia, skin aging, and nail dystrophy resulting from cytotoxic or endocrine agents used in early stages of breast cancer are poorly understood. The objective the study is to describe incidence, clinical pattern, severity risk factors for permanent sequelae adjuvant therapies affecting skin, hair, nails, evaluate their impact on patients quality life (QoL). Methods: This a single-center, prospective, longitudinal cohort non-metastatic...
2564 Background: Cancer patients receiving taxane-based chemotherapy develop alopecia, which may lead to significant psychosocial, quality of life, and adherence issues. Besides a recently FDA-cleared scalp cooling device, there are no oral/ topical agents available prevent CIA. In murine studies, calcitriol reduced CIA, likely due arrest cell cycle in healthy hair follicles, reduction the sensitivity follicular epithelium chemotherapy. Methods: Up 31 adult women with cancer (breast,...
Multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) comprise a fraction of hematologic malignancies diagnosed each year. However, the co-occurrence these conditions in same patient is rare. CD19- maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapies have been approved recent years with promising responses. Here, we present who presented following bone marrow biopsy that revealed MM 20% lambda-restricted plasma cells no evidence involvement marrow. A...
e12533 Background: Endocrine therapies are known to cause adverse events including hot flashes, arthralgias, and dyspareunia. Dermatologic (dAE), alopecia infrequently reported, despite their potential impact on quality of life (QoL). This study aims characterize endocrine therapy-related dAE alopecia, acne, xerosis, onychodystrophy. Methods: A retrospective chart review (2005-2015) patients referred the dermatology service for dermatologic conditions developing during was performed....
e14064 Background: Chemotherapy-induced alopecia (CIA) may lead to significant psychosocial and quality of life issues. Currently there are no FDA approved oral or topical agents available prevent CIA. In murine studies, calcitriol reduced CIA, likely due arrest cell cycle in healthy hair follicles, reduction the sensitivity follicular epithelium chemotherapy. Methods: A prospective dose escalation study is being performed up 31 women with breast cancer, gynecologic cancer sarcomas. Each...